ACE Inhibition and Bradykinin-Mediated Renal Vascular Responses: EDHF Involvement

Hypertension

Volumn 43, Issue 3, 2004, Pages 533-535

  Imig, John D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ; CYTOCHROME P450 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXYICOSATRIENOIC ACID; N METHYLSULFONYL 6 (2 PROPARGYLOXYPHENYL)HEXAMIDE; PROADIFEN; UNCLASSIFIED DRUG;

BLOOD VESSEL REACTIVITY; DRUG EFFECT; EDITORIAL; ENZYME INHIBITION; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY BLOOD VESSEL; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIOLOGICAL FACTORS; BRADYKININ; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; DOGS; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY; NITRIC OXIDE; VASODILATION;

EID: 1442313018     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000118054.86193.ce     Document Type: Editorial

References (22)

1. Matsuda H, Hayashi K, Wakino S, Kubota E, Honda M, Tokuyama H, Takamatsu I, Tatematsu S, Saruta T. Role of endothelium-derived hyperpolarizing factor in ACE inhibitor-induced renal vasodilation in vivo. Hypertension. 2004;43:603-609.
2. Matsuda H, Hayashi K, Arakawa K, Naitoh M, Kubota E, Honda M, Matsumoto A, Suzuki H, Yamamoto T, Kajiya F, Saruta T. Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin. J Am Soc Nephrol. 1999;10:2272-2282.
3. Cowley AW, Roman RJ. The role of the kidney in hypertension. JAMA. 1996;20:1581-1589.
4. Fenoy FJ, Scicli G, Carretero O, Roman RJ. Effect of angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension. 1991;17:1038-1044.
5. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996;78:415-423.
6. Imig JD. Eicosanoid regulation of the renal vasculature. Am J Physiol Renal Physiol. 2000;279:F965-F981.
7. Imig JD, Falck JR, Wei S, Capdevila JH. Epoxygenase metabolites contribute to the nitric oxide-independent afferent arteriolar vasodilation to bradykinin. J Vasc Res. 2001;8:247-255.
8. Wang D, Borrego-Conde LJ, Falck JR, Sharma KK, Wilcox CS, Umans JG. Contribution of nitric oxide, EDHF, and EETs to endothelium-dependent relaxation in renal afferent arterioles. Kidney Int. 2003;63:2187-2193.
9. Ren Y, Garvin JL, Falck JR, Renduchintala KV, Carretero OA. Glomerular autocoids stimulated by bradykinin regulate efferent arteriolar tone. Kidney Int. 2003;63:987-993.
10. i response to angiotensin II of renal juxtamedullary efferent arterioles via an EDHF. Br. J Pharmacol. 2001;132:749-759.
11. Bonetti Po, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Aterioscler Thromb Vasc Biol. 2003;23:168-175.
12. Mancini GB, Henry GC, Maacaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 1996;94:258-265.
13. Kurtz TW. False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system? Hypertension. 2003;41:193-196.
14. Mombouli JV, Vanhoutte PM. Endothelium-derived hyperpolarizing factor(s) and the potentiation of kinins by converting enzyme inhibitors. Am J Hypertens. 1995;8:19S-27S.
15. Campbell WB. New role for epoxyeicosatrienoic acids as antiinflammatory mediators. TiPS. 2000;21:125-127.
16. s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem. 2001;276:15983-15989.
17. Node K, Huo Y, Ruan X, Yang B, Spieker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285:1276-1279.
18. Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, Remuzzi A, Bertocchi F, Fagiani L, Remuzzi G, Ruggenenti P. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 2003;63:1094-1103.
19. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis. 1999;33:851-856.
20. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100:1056-1064.
21. Yang XP, Liu YH, Mehta D, Cavasin MA, Shesely E, Xu J, Liu F, Carretero OA. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type I receptor in B(2) kinin receptor gene knockout mice. Circ Res. 2001;88:1072-1079.
22. Goto K, Fujii K, Onaka U, Abe I, Fujishima M. Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension. 2000;36:575-580.